Skip to main content
Smart Investors Daily
Medtronic plc logo

NASDAQ · MDT

Medtronic plc

Healthcare · Medical - Devices

$100.61

Down-$0.11 (-0.11%)

Updated Nov 20, 2026, 2:19 AM

SID Score

7.1/10

Composite research score

Smart Money

35/100

Bearish

Market cap
127.94B
P/E ratio
26.83
Dividend yield
3.51%
52-week range
$73.31 – $106.20
Volume
5.83M
Avg. volume
7.16M

Price performance · MDT

MDT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

MDT closed at $100.61 after 21 trading sessions, up 4.16% for the selected period.

Last close
$100.61
Period change
+4.16%
Period low
$93.95
Period high
$104.96
Daily close
View OHLC price history
MDT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$100.50$101.50$100.00$100.615.83M
Nov 18, 2026$100.86$102.46$99.59$100.726.87M
Nov 17, 2026$102.75$103.84$102.12$102.325.35M
Nov 16, 2026$103.82$104.49$102.85$102.886.8M
Nov 13, 2026$102.10$103.34$101.41$102.865.26M
Nov 12, 2026$102.45$102.90$100.92$100.996.1M
Nov 11, 2026$100.70$101.815$100.02$101.614.39M
Nov 10, 2026$102.19$102.627$100.80$101.595.05M
Nov 9, 2026$102.72$103.69$101.53$102.795.74M
Nov 6, 2026$101.54$103.07$100.8036$101.807.45M
Nov 5, 2026$106.05$106.20$103.31$104.8411.65M
Nov 4, 2026$100.20$105.72$99.80$104.9611.57M
Nov 3, 2026$98.60$99.95$98.17$98.886.82M
Nov 2, 2026$96.94$99.48$96.75$99.298.77M
Oct 30, 2026$98.00$98.09$96.46$96.548.68M
Oct 29, 2026$96.47$97.195$95.17$97.119.38M
Oct 28, 2026$93.06$95.715$93.0401$94.789.58M
Oct 27, 2026$94.25$94.53$93.74$93.955.45M
Oct 26, 2026$95.00$95.70$94.09$94.798.46M
Oct 23, 2026$96.10$96.89$95.38$95.416.01M
Oct 22, 2026$93.48$96.66$93.12$96.598.88M

Latest MDT news

The latest Smart Investors Daily articles mentioning MDT.

MDT research

Overview

Company profile and research snapshot.

Company profile

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$111.50
Implied upside
—
Analysts
22
MDT recent ratings
DateFirmRatingTarget
Nov 19, 2026BTIGBuy—
Nov 17, 2026Piper SandlerOverweight—
Oct 12, 2026BTIGBuy—
Oct 7, 2026BarclaysEqual-Weight—
Sep 30, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

Ex-Medtronic CEO grades Nvidia board: 'About an F'

Yahoo Finance Executive Editor Brian Sozzi is joined by former Medtronic (MDT) CEO Bill George, who grades the Nvidia (NVDA) board's makeup, its handling of Jensen Huang's departure, and its succession plan.

Yahoo · Nov 11, 2026

What Is Medtronic (MDT) Facing After Two Class II Cardiac Device Recalls?

Medtronic (NYSE:MDT) initiated two Class II device recalls in November 2026 covering cardiac products used in implantable therapies. The OmniaSecure Model 3930M cardiac lead recall cites product performance concerns, including difficulties with lead fixation during implantation. The CareLink SmartSync Programmer recall focuses on software issues that can produce inaccurate estimates of implanted device battery longevity. The twin recalls of the OmniaSecure 3930M lead and CareLink SmartSync...

Yahoo · Nov 7, 2026

Can Medtronic (MDT) Still Justify Its Price On Cash Flow?

Medtronic has delivered a 58.9% share price gain over the past three years, and the real question now is whether that kind of run is still supported by the cash the business can generate. With fresh clinical data, updated product labeling and new educational partnerships in the spotlight, the stock invites a closer look at how its current price lines up against an intrinsic value estimate built on its cash flows. The 58.9% return over three years places more focus on whether recent share...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.